open access
Does canagliflozin decrease natriuretic peptide levels in patients with diabetes and heart failure?
, 12, 12, 12, 12, 12
Affiliations- Department of Cardiology, Hospital Universitario Reina Sofía, Córdoba, Spain
- Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Universidad de Córdoba, Córdoba, Spain
open access
Abstract
Abstract
About this articleTitle
Does canagliflozin decrease natriuretic peptide levels in patients with diabetes and heart failure?
Journal
Issue
Article type
Research Letter
Pages
166-169
Published online
2021-12-17
Page views
5197
Article views/downloads
655
DOI
Pubmed
Bibliographic record
Cardiol J 2022;29(1):166-169.
Authors
Ernesto Martín
Juan C. Castillo
Rafael González-Manzanares
José López Aguilera
Jorge Perea
Manuel Anguita
References (9)- Zinman B, Wanner C, Lachin J, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Eng J Med. 2015; 373(22): 2117–2128.
- Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017; 377(7): 644–657.
- Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380(4): 347–357.
- McMurray JJV, Solomon SD, Inzucchi SE. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Eng J Med. 2019; 381(20): 1995–2008.
- Packer M, Anker SD, Butler J, et al. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol. 2017; 2(9): 1025–1029.
- Nassif ME, Windsor SL, Tang F, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. Circulation. 2019; 140(18): 1463–1476.
- Januzzi JL, Butler J, Jarolim P, et al. Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes. J Am Coll Cardiol. 2017; 70(6): 704–712.
- Damman K, Beusekamp JC, Boorsma EM, et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail. 2020; 22(4): 713–722.
- Garg V, Verma S, Connelly K. Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes. Prog Cardiovasc Dis. 2019; 62(4): 349–357.
